Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387088 · ClinicalTrials.gov registry record · Phase 3
Tiotropium / Respimat One Year Study in COPD.
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,991
- Enrollment target
NCT00387088 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 3,991 participants.
The verdict
NCT00387088, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,991 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.
Interventions
- DRUG Tiotropium
- DEVICE Respimat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,991 participants |
| Start Date | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387088
The ClinicalTrials.gov registry entry for NCT00387088 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,991 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium is the first listed.
NCT00387088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387088 about?
NCT00387088 is a clinical study titled "Tiotropium / Respimat One Year Study in COPD.". The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.
What is the current status of trial NCT00387088?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,991 participants. The study started on 2006-09.
What interventions are being tested in trial NCT00387088?
The interventions under investigation include: Tiotropium (DRUG), Respimat (DEVICE).
Who is sponsoring clinical trial NCT00387088?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.